Pancreatic Cancer Research

ResearcherWayne State UniversityActive in the last 2 years

Anthony Frank Shields

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9122-1014; OpenAlex author ID A5072203753. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 2)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
86
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper, 1 trial · 2015: 1 paper, 1 trial · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 17

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  3. Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-3149↗
  4. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  5. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  6. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Co-author DOI 10.1002/ctm2.1513↗
  7. Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer … Co-author DOI 10.1101/2022.03.08.481108↗
  8. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-3581↗
  9. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  10. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Last author DOI 10.1080/2162402x.2020.1773201↗
  11. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  12. Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designat… Co-author DOI 10.1097/coc.0000000000000507↗
  13. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenoc… Co-author DOI 10.1200/jco.18.01295↗
  14. Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) Last author DOI 10.1186/2051-1426-3-s2-p55↗
  15. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advan… Co-author DOI 10.1016/j.radonc.2014.08.014↗
  16. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy:… Co-author DOI 10.1002/cncr.27734↗
  17. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Co-author DOI 10.1007/s10637-010-9386-6↗

Trials 2

  1. BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Principal investigator NCT02620865↗
  2. hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Principal investigator NCT02960594↗

Closest collaborators

The 25 strongest of 86 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Philip A. Philip · 10 shared papers, 2011–2023 · strength 0.78
  2. Sahar F. Bannoura · 4 shared papers, 2022–2026 · strength 0.64
  3. Md. Hafiz Uddin · 4 shared papers, 2022–2026 · strength 0.64
  4. Husain Yar Khan · 4 shared papers, 2022–2026 · strength 0.64
  5. Amro Aboukameel · 4 shared papers, 2022–2026 · strength 0.64
  6. Asfar Sohail Azmi · 4 shared papers, 2022–2026 · strength 0.64
  7. Emil Lou · 4 shared papers, 2022–2025 · strength 0.61
  8. Steve H. Kim · 3 shared papers, 2022–2025 · strength 0.44
  9. Bassel F. El‐Rayes · 4 shared papers, 2011–2026 · strength 0.43
  10. Wafik S. El‐Deiry · 3 shared papers, 2020–2024 · strength 0.37
  11. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  12. Bin Bao · 2 shared papers, 2025–2026 · strength 0.37
  13. Boris Pasche · 2 shared papers, 2025–2026 · strength 0.37
  14. Eliza Wright Beal · 2 shared papers, 2025–2026 · strength 0.37
  15. Muhammad Wasif Saif · 2 shared papers, 2025–2026 · strength 0.37
  16. Ramzi M. Mohammad · 2 shared papers, 2025–2026 · strength 0.37
  17. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  18. Andreas Seeber · 3 shared papers, 2020–2024 · strength 0.36
  19. Heinz‐Josef Lenz · 3 shared papers, 2020–2024 · strength 0.36
  20. Michael J. Hall · 4 shared papers, 2014–2022 · strength 0.35
  21. Wolfgang Michael Korn · 3 shared papers, 2020–2022 · strength 0.31
  22. John Lindsay Marshall · 3 shared papers, 2020–2022 · strength 0.31
  23. Davendra P. S. Sohal · 2 shared papers, 2022–2024 · strength 0.29
  24. Yiwei Li · 2 shared papers, 2022–2023 · strength 0.27
  25. Ibrahim Hanna Azar · 2 shared papers, 2022–2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.